Tangential flow filtration as a novel approach for fluorescent tracer purification and production up-scaling: cetuximab-800CW and ustekinumab-800CW as a proof-of-concept.
- 1Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
- 2Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Abstract
Fluorescence molecular imaging using fluorescently labeled antibodies enables identification of target cells and provides pharmacological insight into local drug distribution. The current GMP manufacturing method of tracers using PD-10 columns is subject to methodological constraints when handling low antibody concentrations, large quantities, or incompatible antibodies. This study presents Tangential Flow Filtration (TFF) as a novel and scalable approach to manufacture clinical-grade fluorescent tracers and demonstrates its applicability using cetuximab-800CW and ustekinumab-800CW. TFF system settings were optimized for purification of cetuximab-800CW and ustekinumab-800CW with labeling parameters and quality control similar to tracer production with PD-10 columns. Cetuximab-800CW production was successfully transitioned from PD-10 to TFF. QC-data after manufacturing with TFF (n = 7) or PD-10 (n = 21) were compared at release and up to 24 months of storage at 2-8°C. This revealed TFF purification to be more efficient and robust, with label efficiencies of 93.5 ± 2.3% with TFF compared to 68.3 ± 6.9% with PD-10, and 0.0 ± 0.1% unconjugated dye with TFF compared to 0.5 ± 0.3% with PD-10. Stability data were comparable for both methods. TFF manufacturing yielded clinical-grade cetuximab-800CW batches stable for at least 24 months. Concentrations ranged from 0.99-1.08 mg/mL and target binding affinity from 65-98%. Detected free dye and aggregates remained well below 3.0%. Moreover, ustekinumab-800CW was successfully manufactured using TFF after PD-10 manufacturing failed due to particle formation. Ustekinumab-800CW was stable up to 24 months at 2-8°C. Together, this demonstrates the feasibility of using TFF for clinical-grade fluorescent tracer manufacturing under GMP conditions.
Related
- A Platform Approach to mRNA Purification by Tangential Flow Filtration: Application to a Pentavalent Norovirus Vaccine.
- An efficient system for production of highly purified inhibins using mammalian cell expression and tandem affinity purification
- Genetically Expanded Fluorescent SSBT7 RNA Polymerase in Action: Intriguing Photophysics with Enhanced RNA Production
- Isolation to purification: An integrated study on lysine production by Bacillus megaterium NTJT4 from medicinal plant rhizosphere
- From Exosomal Cargo to In Vivo Causality: Interpreting the miR-146a-5p/SMAD4 Axis After Glaucoma Filtration Surgery
BibTeX
@article{huizinga2026tangential,
title = {{Tangential flow filtration as a novel approach for fluorescent tracer purification and production up-scaling: cetuximab-800CW and ustekinumab-800CW as a proof-of-concept.}},
author = {Henrik K Huizinga and Rosalie J van Dijken and Bahez Gareb and Bart G J Dekkers and Jacoba van Zanten and Hans H Westra and Pauline Koopmans and Wouter B Nagengast and Marjolijn N Lub-de Hooge},
journal = {MAbs},
year = {2026},
month = oct,
doi = {10.1080/19420862.2026.2743444},
url = {https://europepmc.org/article/MED/42850075},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Tangential flow filtration as a novel approach for fluorescent tracer purification and production up-scaling: cetuximab-800CW and ustekinumab-800CW as a proof-of-concept.
AU - Henrik K Huizinga
AU - Rosalie J van Dijken
AU - Bahez Gareb
AU - Bart G J Dekkers
AU - Jacoba van Zanten
AU - Hans H Westra
AU - Pauline Koopmans
AU - Wouter B Nagengast
AU - Marjolijn N Lub-de Hooge
PY - 2026
DA - 2026/10/08
JO - MAbs
DO - 10.1080/19420862.2026.2743444
UR - https://europepmc.org/article/MED/42850075
AB - Fluorescence molecular imaging using fluorescently labeled antibodies enables identification of target cells and provides pharmacological insight into local drug distribution. The current GMP manufacturing method of tracers using PD-10 columns is subject to methodological constraints when handling low antibody concentrations, large quantities, or incompatible antibodies. This study presents Tangential Flow Filtration (TFF) as a novel and scalable approach to manufacture clinical-grade fluorescent tracers and demonstrates its applicability using cetuximab-800CW and ustekinumab-800CW. TFF system settings were optimized for purification of cetuximab-800CW and ustekinumab-800CW with labeling parameters and quality control similar to tracer production with PD-10 columns. Cetuximab-800CW production was successfully transitioned from PD-10 to TFF. QC-data after manufacturing with TFF (n = 7) or PD-10 (n = 21) were compared at release and up to 24 months of storage at 2-8°C. This revealed TFF purification to be more efficient and robust, with label efficiencies of 93.5 ± 2.3% with TFF compared to 68.3 ± 6.9% with PD-10, and 0.0 ± 0.1% unconjugated dye with TFF compared to 0.5 ± 0.3% with PD-10. Stability data were comparable for both methods. TFF manufacturing yielded clinical-grade cetuximab-800CW batches stable for at least 24 months. Concentrations ranged from 0.99-1.08 mg/mL and target binding affinity from 65-98%. Detected free dye and aggregates remained well below 3.0%. Moreover, ustekinumab-800CW was successfully manufactured using TFF after PD-10 manufacturing failed due to particle formation. Ustekinumab-800CW was stable up to 24 months at 2-8°C. Together, this demonstrates the feasibility of using TFF for clinical-grade fluorescent tracer manufacturing under GMP conditions.
SN - 1942-0862
SN - 1942-0870
ER -